Holigos® IBS 

Relief for patients that’s safe, well-tolerated, and effective in a once-daily dose.1-5

Help your patients discover the difference with a free 28-day supply of Holigos® IBS.

Holigos® IBS 

Relief for patients that’s safe, tolerable, and effective in one daily dose.1-5

Help your patients discover the difference with a free 28-day supply of Holigos® IBS.

Holigos® IBS 

Relief for patients that’s safe, well-tolerated, and effective in a once-daily dose.1-5

Help your patients discover the difference with a free 28-day supply of Holigos® IBS.

Clinical Benefits

Holigos® IBS is clinically proven to help provide relief in all IBS subtypes.

In a 12-week, open-label, multi-center study (N=317),* Holigos® IBS demonstrated five key benefits2:

Clinical Benefits

Holigos® IBS is clinically proven to help provide relief in all IBS subtypes.

In a 12-week, open-label, multi-center study (N=317) study,* Holigos® IBS demonstrated five key benefits2:


Decreased Severity

IBS severity changed from severe to mild by Week 12, as measured by the IBS-severity scoring system (IBS-SSS)

  • Over 95% of patients (PP, n=245) had a clinically significant improvement in their IBS-SSS total score by Week 12
  • A reduction of 50 points or more in the IBS-SSS total score is considered clinically significant6

58% decrease in abdominal pain severity per IBS-SSS pain subcomponent, P<0.0001

Decreased Severity

IBS severity changed from severe to mild by Week 12, as measured by the IBS-severity scoring system (IBS-SSS)

  • Over 95% of patients (PP, n=245) had a clinically significant improvement in their IBS-SSS total score by Week 12
  • A reduction of 50 points or more in the IBS-SSS total score is considered clinically significant6

58% decrease in abdominal pain severity per IBS-SSS pain subcomponent, P<0.0001


Fewer Days With Pain

Reduced from an average of 6.1 to 2.6 days within the prior 10 days, P<0.0001

Normalized Stools

Over 6-fold increase in normal stools from a baseline of 7% as measured by the Bristol Stool Form Scale (BSFS)

Quality of Life

Quality of Life

49% increase in quality of life scores using the IBS-QOL assessment, P<0.00012‖


Patients experienced improvement in abdominal pain, bloating, and stool consistency in as early as 4 weeks.1,2

No difference in efficacy among patients with IBS-C, IBS-D, and IBS-M

IBS-C=irritable bowel syndrome with constipation; IBS-D=irritable bowel syndrome with diarrhea; M: IBS-M=irritable bowel syndrome with mixed bowel habits; ITT=intention-to-treat; PP=per-protocol.

The proof is in our product. Help your patients discover the difference with a FREE 28-day supply of Holigos® IBS.


MECHANISM OF ACTION OF HOLIGOS® IBS

MECHANISM OF ACTION OF HOLIGOS® IBS

While others target the symptoms, we target the source.1,2,5,7,8

1.

Bacterial dysbiosis is a key driver of IBS pathology and is common in IBS patients.9-13

1.

Bacterial dysbiosis is a key driver of IBS pathology and is common in IBS patients.9-13

2.

Microbiome dysbiosis can impair normal gut metabolism.9,10,12,14,15

2.

Microbiome dysbiosis can impair normal gut metabolism.9,10,12,14,15

2.

Microbiome dysbiosis can impair normal gut metabolism.9,10,12,14,15

3.

Abnormal gut metabolism can exacerbate symptoms of IBS through disruption in gut barrier function.12,15,16

3.

Abnormal gut metabolism can exacerbate symptoms of IBS through disruption in gut barrier function12,15,16

3.

Abnormal gut metabolism can exacerbate symptoms of IBS through disruption in gut barrier function.12,15,16

4.

The glycans in Holigos® IBS help rebalance the gut microbiome and increase production of beneficial metabolites.1-3,5,17

4.

The glycans in Holigos® IBS help rebalance the gut microbiome and increase production of beneficial metabolites 1-3,5,17

4.

The glycans in Holigos® IBS help rebalance the gut microbiome and increase production of beneficial metabolites.1-3,5,17

5.

The glycans in Holigos® IBS improve gut motility and gut barrier integrity.1,2,5,17

5.

The glycans in Holigos® IBS improve gut motility and gut barrier integrity1,2,5,17

5.

The glycans in Holigos® IBS improve gut motility and gut barrier integrity.1,2,5,17

Holigos® IBS helps reduce symptoms by addressing the distinct nutritional requirements of patients with IBS.1,2,5

SAFETY & TOLERABILITY

Holigos® IBS is safe and well-tolerated.

In a double-blinded, placebo-controlled trial2:

No difference in reported adverse events between Holigos® IBS and placebo.

No serious adverse events with Holigos® IBS or placebo reported.

Common side effects associated with Holigos® IBS included mild local reactions in the gut, such as abdominal pain, distension, and flatulence.


The ingredients in Holigos® are safe and well-tolerated by infants, children, adults, and patients with IBS.1-5

 
DOSING
Holigos® IBS is a nonprescription medical food available as a once-daily dose.
Holigos® IBS is easy to take and has been formulated to help normalize the gut microbiota.1,2,5,17

Holigos ® IBS is a proprietary blend of the glycans 2’-FL and LNnT, which have been granted the designation of generally recognized as safe by the Food and Drug Administration (FDA).2

Does not contain gluten, added colors or flavors, or yeast.
 
DOSING
Holigos® IBS is a nonprescription medical food available as a once-daily dose.
Holigos® IBS is easy to take and has been formulated to help normalize the gut microbiota.1,2,5,17

Holigos ® IBS is a proprietary blend of the glycans 2’-FL and LNnT, which have been granted the designation of generally recognized as safe by the Food and Drug Administration (FDA).2

Does not contain gluten, added colors or flavors, or yeast.

 

The proof is in our product.

Let your patients sample Holigos® IBS free to discover the difference.

If you are a registered healthcare professional with patients who have IBS, we would be delighted to provide you with free samples and coupons for your patients.

  • I have received a sample
  • Request samples for my patients

*Required fields

*Required fields

The proof is in our product.

Let your patients sample Holigos® IBS free to discover the difference.

If you are a registered healthcare professional with patients who have IBS, we would be delighted to provide you with free samples and coupons for your patients.

  • I have received a sample
  • Request samples for my patients

*Required fields

*Required fields

Footnotes & References

  • *The GRIPS clinical trial was a 12-week, multi-center, open-label trial in patients with IBS (ITT, N=317; PP, n=245) to assess the potential for Holigos® IBS to induce and support normal bowel habits and improve symptoms of IBS. The primary endpoint was effect on stool consistency. Select secondary outcomes included: IBS-SSS total score, IBS-SSS abdominal pain severity and stool frequency, IBS abdominal distension severity, and health-related quality of life.2
  • †The IBS-SSS assesses symptom severity by measuring abdominal pain intensity and frequency, abdominal distension, dissatisfaction with bowel habits, and life interference of IBS during the preceding week. The total IBS-SSS score ranges between 0 and 500; a higher score indicates more severe symptoms.6
  • §The BSFS classifies the form of human feces into seven categories, running from 1=“separate hard lumps” to 7=“watery”. Abnormal stools is the total % of all stools that are either Bristol Types 1-2 or 6-7.18
  • ‖The IBS-QOL measures the impact of IBS and its treatment, which consists of 34 items; a higher score indicates better QOL.19
  • ¶Medical foods are specifically formulated for the dietary management of a disease or condition for which there are distinctive nutritional requirements to be adhered to under the guidance of a medical professional.20

References

  1. Elison E, Vigsnaes LK, Krogsgaard LR, et al. Oral supplementation of healthy adults with 2’-O-fucosyllactose and lacto-N-neotetraose is well tolerated and shifts the intestinal microbiota. Br J Nutr. 2016;116(8):1356-1368.
  2. Data on File. Glycom A/S. 2019.
  3. Puccio G, Alliet P, Cajozzo C, et al. Effects of infant formula with human milk oligosaccharides on growth and morbidity: A randomized multicenter trial. J Pediatr Gastroenterol Nutr. 2017;64(4):624-631.
  4. Storm HM, Shepard J, Czerkies LM, et al. 2′-Fucosyllactose is well tolerated in a 100% whey, partially hydrolyzed infant formula with bifidobacterium lactis : a randomized controlled trial. Glob Pediatr Heal. 2019;6:1-10.
  5. Iribarren C, Törnblom H, Aziz I, et al. The effects of human milk oligosaccharides on bifidobacteria and gastrointestinal symptoms in irritable bowel syndrome patients: a parallel, double blind, randomized, placebo-controlled trial. In: Gastroenterology. ; 2019.
  6. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395-402.
  7. Salomonsson E, Vigsnaes L, Sommer M, Hennet T, Bytzer P. Human milk oligosaccharides; now as substantial modulators of the adult gut microbiota. In: International Scientific Conference on Probiotics and Prebiotics. Budapest; 2016:114.
  8. Wald A. Treatment of irritable bowel syndrome in adults. In: Nicholas JT, Shilpa G. UpToDate. https://www.uptodate.com/contents/treatment-of-irritable-bowel-syndrome-in-adults/. Published 2019. Accessed July 16, 2019.
  9. Duboc H, Rainteau D, Rajca S, et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2012;24(6).
  10. Dior M, Delagrèverie H, Duboc H, et al. Interplay between bile acid metabolism and microbiota in irritable bowel syndrome. Neurogastroenterol Motil. 2016;28(9):1330-1340.
  11. Bennet SMP, Sundin J, Magnusson MK, et al. Altered intestinal antibacterial gene expression response profile in irritable bowel syndrome is linked to bacterial composition and immune activation. Neurogastroenterol Motil. 2018;30(12):1-15.
  12. Rajilić-Stojanović M, Jonkers DM, Salonen A, et al. Intestinal microbiota and diet in IBS: Causes, consequences, or epiphenomena? Am J Gastroenterol. 2015;110(2):278-287.
  13. Tap J, Derrien M, Törnblom H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017;152(1):111-123.
  14. Bhattarai Y, Muniz Pedrogo DA, Kashyap PC. Irritable bowel syndrome: a gut microbiota-related disorder? Am J Physiol Liver Physiol. 2017;312(1):G52-G62.
  15. Postler TS, Ghosh S. Understanding the Holobiont: How Microbial Metabolites Affect Human Health and Shape the Immune System. Cell Metab. 2017;26(1):110-130.
  16. Martin-Gallausiaux C, Larraufie P, Jarry A, et al. Butyrate produced by commensal bacteria down-regulates indolamine 2,3-dioxygenase 1 (IDO-1) expression via a dual mechanism in human intestinal epithelial cells. Front Immunol. 2018;9(2838):1-13.
  17. Bode L. The functional biology of human milk oligosaccharides. Early Hum Dev. 2015;91(11):619-622.
  18. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920-924. Accessed July 17, 2019.
  19. Patrick DL, Drossman DA, Frederick IO, Dicesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure. Dig Dis Sci. 1998;43(2):400-411.
  20. US Food & Drug Administration. Medical foods guidance documents & regulatory information. https://www.fda.gov/food/guidance-documents-regulatory-information-topic-food-and-dietary-supplements/medical-foods-guidance-documents-regulatory-information. Accessed July 16, 2019.